Table 1.
General data of the observation group and control group.
| Observation group (n = 66) | Control group (n = 66) | p | |
|---|---|---|---|
| Sex (male) | 57 (86.4) | 55 (83.3) | 0.627 |
| Age (Y) | 63.70 ± 9.46 | 61.12 ± 9.57 | 0.122 |
| Body mass index (BMI) | 22.94 ± 4.99 | 23.51 ± 4.80 | 0.509 |
| Tumor type [n (%)] | 0.307 | ||
| Cancer of the esophagus | 44 (66.7) | 45 (68.2) | |
| Cancer of the gastroesophageal junction | 19 (28.8) | 21 (31.8) | |
| Postoperative recurrence | 3 (4.5) | 0 (0) | |
| Pathological T stage [n (%)]a | 0.989 | ||
| Tis | 1 (1.5) | 2 (3.0) | |
| T0 | 5 (7.6) | 4 (6.1) | |
| T1 | 17 (25.8) | 16 (24.2) | |
| T2 | 10 (15.2) | 10 (15.2) | |
| T3 | 25 (37.9) | 29 (43.9) | |
| T4 | 5 (7.6) | 5 (7.6) | |
| Pathological N stage [n (%)]a | 0.569 | ||
| N0 | 33 (50.0) | 28 (42.4) | |
| N1 | 15 (22.7) | 16 (24.3) | |
| N2 | 7 (10.6) | 8 (12.1) | |
| N3 | 8 (12.1) | 14 (21.2) | |
| Neoadjuvant therapy [n (%)] | 40 (60.6) | 51 (77.3) | 0.112 |
| Neoadjuvant chemotherapy | 24 (36.4) | 36 (54.5) | |
| Neoadjuvant chemoradiotherapyb | 4 (6.1) | 3 (4.5) | |
| Neoadjuvant chemotherapy + immunotherapy | 11 (16.7) | 10 (15.2) | |
| Other neoadjuvant therapies | 1 (1.5) | 2 (3.0) | |
| ASA classification [n (%)] | 0.778 | ||
| I | 0 (0) | 1 (1.5) | |
| Ⅱ | 58 (87.9) | 59 (89.4) | |
| Ⅲ | 8(12.1) | 6(9.1) | |
| Ⅳ | 0(0) | 0(0) |
a
The patients in the observation group did not include 3 patients with postoperative recurrence.
b
The radiotherapy plan was not completed by one patient due to discontinuation of radiotherapy.